Using 68Ga-HA-DOTATATE PET/CT to Diagnose Neuroendocrine Tumors
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
This study is testing a new type of imaging called 68Ga-HA-DOTATATE PET/CT to see if it can better diagnose certain neuroendocrine tumors compared to regular imaging methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Alberta Health services Academic / other |
| Locations | 1 site (Calgary, Alberta) |
| Trial ID | NCT05673031 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga-HA-DOTATATE PET/CT imaging in diagnosing somatostatin positive neuroendocrine tumors compared to conventional imaging methods such as CT, MRI, and other PET scans. It aims to determine the utility of this imaging technique in the primary workup of suspected neuroendocrine tumors and in the surveillance of completely resected tumors. Additionally, the study will assess its role in localizing functioning neuroendocrine tumors like insulinoma and gastrinoma. Participants will undergo imaging to compare results with standard diagnostic approaches.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with clinically suspected or biopsy-proven neuroendocrine tumors.
Not a fit: Patients who are pregnant, nursing, or have had surgery in the area of interest within the last two months may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could improve the accuracy of diagnosing neuroendocrine tumors, leading to better patient management.
How similar studies have performed: While this approach is being evaluated, similar imaging techniques have shown promise in diagnosing neuroendocrine tumors, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required. 2. Age greater than or equal to 18 years. 3. Able and willing to follow instructions and comply with the protocol. 4. Provide written informed consent prior to participation in the study. 5. Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor Exclusion Criteria: 1. Nursing or pregnant females. 2. Age less than 18 years. 3. Surgery in the area of interest within the preceding 2 months.
Where this trial is running
Calgary, Alberta
- Foothills Medical Center 1403 29 St NW — Calgary, Alberta, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.